STEM Skills in Synergy for Pharmaceutical Development

From Idea to Drug: A Multi-Billion-Dollar Journey

Drug development requires 12-15 years and over one billion dollars, involving dozens of STEM disciplines working in synergy. Medicinal chemists, biologists, computer scientists, engineers, and physicians collaborate in an iterative cycle from molecular target identification to human clinical trials. It is a concrete example of how interdisciplinarity drives modern scientific innovation.

The journey to transform a scientific insight into an effective drug is one of the most complex and expensive human endeavors. A process that can take on average 12 to 15 years and exceed one billion dollars in investment.

Contrary to popular belief, this odyssey of drug discovery and development is not the work of a single genius but the result of an intense multidisciplinary collaboration, driven by a broad spectrum of STEM skills (Science, Technology, Engineering, and Mathematics).

At the centre of this process, with a role that evolves and becomes increasingly crucial at every step, is medicinal chemistry. Medicinal chemists are the molecular architects who transform a biological idea into a molecule capable of interacting with structures within the human body (or of other invading organisms, in the case of antimicrobials, for example). From design to synthesis to the optimisation of every single property, they are the ones who build the drug, atom by atom.

Let us explore how chemists, biologists, mathematicians, computer scientists, engineers, and physicians work in synergy to carry this journey forward, from the laboratory to the patient's bedside.

Phase 1: Target Identification & Validation

The most critical and initial phase of the drug discovery process is the identification and validation of the biological target. A target is a molecule — often a protein, gene, or RNA — whose activity or function is associated with a specific disease. The idea is that by modulating the activity of this target (for example, by blocking or activating it), the disease can be treated or prevented. For example, in the case of type 2 diabetes, a target could be a receptor that regulates glucose metabolism.

Historical Example

A historical example of a drug based on a molecular target is Imatinib mesylate, developed to treat chronic myeloid leukemia (CML). STEM skills were essential to identify a specific fusion protein, Bcr-Abl, as the critical target of the disease.

In this initial phase, the chemist's role is not yet centred on large-scale synthesis but is fundamental for target validation through Chemical Genomics. This integrated discipline combines chemical synthesis with biology to study the genomic response to "tool" molecules.

Chemists design and synthesize small molecules that are not destined to become drugs but serve to modulate the target's activity in a specific manner and study the effects of such modulation at the cellular and molecular level. This approach is essential for confirming the correlation between the target and the disease before investing billions in developing a potential drug.

The remainder of this phase is dominated by other disciplines:

• Molecular Biology and Genetics: To analyse mRNA and protein levels in diseased and healthy tissues and identify the genetic causes of a pathology. These foundational STEM skills are the first spark of the process.
• Bioinformatics and Data Science: Essential for analysing enormous amounts of biomedical data and prioritising potential targets — finding the proverbial needle in the haystack. The use of algorithms and computational models applied to chemistry and cellular and molecular biology is a perfect example of how STEM skills integrate in service of humanity.
• Cell Biology and Immunology: Crucial for phenotypic screening and for developing validation technologies such as monoclonal antibodies (mAbs) or RNA-based technologies. Understanding how cells respond to stimuli is one of the most important STEM skills.

Phase 2: Hit Discovery

Once the target has been discovered, identified, and validated, the next step is to actively search for molecules that can interact with it.

A hit is a molecule that shows the desired biological activity against the target in an initial assay. A hit is the first promising molecule, but it has not yet been optimised to become a drug.

In this phase, the medicinal chemist's contribution manifests in three main ways, once again demonstrating the importance of cross-cutting STEM skills:

• Design of Chemical Libraries: Large pharmaceutical companies do not test molecules at random. Medicinal chemists, in collaboration with biologists, design and curate compound libraries that are chemically diverse and biologically relevant. This phase requires deep knowledge of molecule classes known for their activity and of the rules that make a molecule "drug-like" (that is, having properties suitable for becoming a drug).
• Virtual Screening: In collaboration with computational chemists and computer scientists, medicinal chemists and biologists use molecular modelling software to perform virtual screening. They simulate the binding (so-called "docking") between billions of virtual compounds and the 3D model of the protein target. This allows filtering the most promising candidates before even synthesizing them, drastically reducing time and costs.
• High Throughput Screening (HTS): This process, made possible by STEM skills in robotics and automation engineering, is the backbone of this phase. HTS is an automated screening method that allows rapid testing of millions of chemical compounds in small containers, such as 96-, 384-, or 1536-well plates.
• Synthesis and Characterization: When a "hit" is identified, the chemist's work does not stop. Using skills in organic synthesis and analytical chemistry, the chemist must re-synthesize the compound to confirm its activity and verify its structure and purity.

Phase 3: Hit-to-Lead and Lead Optimisation

After identifying the "hits," the task is to select the best ones and improve their properties.

A lead is a "hit" that has been optimised and has demonstrated a promising profile for becoming a drug.

The goal is to transform the lead into a compound with ideal potency, selectivity, safety, and pharmacokinetic properties. This phase is the true proving ground for the medicinal chemist's STEM skills and organic synthesis expertise, with strong support from other disciplines such as biology, pharmacology, mathematics, and computer science.

The Design and Synthesis Cycle: The Engine of Innovation

This phase proceeds through an iterative cycle known as Design-Make-Test-Analyse (DMTA), where the medicinal chemist is the central pivot:

• Design: The medicinal chemist, based on biological and pharmacological data, designs and optimises the lead's chemical structure. This design is a balancing act: potency must be improved, but so must selectivity; solubility must be increased, but without compromising permeability.
• Make: With expertise in organic synthesis, the chemist physically creates the molecule, producing it on a laboratory scale (a few grams). This may require complex, multi-step processes, starting from basic molecules (building blocks) and assembling them with precise and controlled chemical reactions.
• Test: The synthesized molecule is sent to biologists and pharmacologists to be tested in a series of assays that evaluate its efficacy, selectivity, and safety.
• Analyse: The biological and pharmacological test data return to the medicinal chemist, who analyses them to understand how molecular structure influences biological properties.

Structure-Activity Relationships (SAR): The Art of Optimisation

Data analysis leads to understanding Structure-Activity Relationships (SAR). An experienced medicinal chemist knows that small structural modifications can have enormous impacts on a compound's properties.

For example, adding a methyl group (-CH3) can improve solubility or metabolic stability, while substituting an oxygen atom with a sulfur atom can increase potency. SAR is the scientific guide that allows navigating the vast "valley" of possible molecules to find the "peak" representing the optimal compound.

The Role in Pharmacokinetics and Toxicology

Chemists do not limit themselves to creating potent molecules — they are also responsible for designing molecules with a favourable pharmacological profile, another essential STEM skill.

This translates into a series of efforts aimed at improving not only the efficacy but especially the safety profile of a molecule that is not yet a drug but is beginning to meet a number of requirements to potentially become one.

ADME-T Profile

• ADME (Absorption, Distribution, Metabolism, Excretion): ADME properties are crucial for the drug's ability to act in the body. The medicinal chemist designs the molecule to optimise its solubility and permeability (to cross cell membranes and reach the target), its resistance to metabolism by hepatic enzymes (such as CYP450), and its ability to be eliminated safely.
• Toxicology: The medicinal chemist is at the forefront of designing safe molecules. Specific skills allow identifying and mitigating potential side effects, such as hERG channel inhibition, which can cause cardiac problems, or genotoxic potential.

Preclinical Development

Before the chosen candidate can be tested in humans, it must pass the preclinical development phase.

This phase is crucial for establishing the drug's safety, pharmacological profile, and toxicological potential. The interdisciplinarity of STEM skills is here more evident than ever. Scientists, including pharmacologists, toxicologists, and biochemists, conduct a series of in vitro (on laboratory cells) and in vivo (on animal models) studies to:

• Pharmacology and Pharmacokinetics: Detailed tests are conducted to understand how the drug distributes, metabolizes, and is eliminated from the animal's body, providing essential data for estimating the safe and effective dose in humans.
• Toxicology: Rigorous studies on acute and chronic toxicity are conducted to identify potential short- and long-term side effects.
• Pathology: Pathologists examine treated cells and tissues to identify any drug-induced cellular or tissue damage.

This meticulous work is supported by robust statistics and bioinformatics for analysing complex data. Only if the candidate successfully passes this phase can it be considered eligible for subsequent clinical development stages.

The preclinical candidate is the selected compound, with the best profile in terms of potency, selectivity, safety, and pharmacokinetic properties, that is ready for human clinical trials.

At this point, the chemist's responsibility shifts from laboratory-scale optimisation to large-scale production — the industrial kind.

Process Chemistry

This branch of chemical engineering is fundamental for scale-up (increasing production). Process chemists optimise synthesis to make it efficient, safe, and economically sustainable on an industrial scale.

They develop synthesis pathways that reduce the number of steps, use less toxic reagents and solvents, and generate less waste, making drug production feasible for the market and suitable for human administration.

Conclusion: Interdisciplinarity as the Engine of Progress

The drug discovery journey does not end here. The preclinical candidate must still pass the various phases of human clinical trials (Phase I, II, and III) before it can receive approval from regulatory authorities.

It is in this phase that the role of the physician comes massively into play. A physician specialising in clinical research (the Clinical Investigator) is responsible for enrolling patients, administering the drug, and monitoring therapeutic effects and any adverse events.

The physician is the bridge between laboratory science and clinical reality, providing crucial feedback to scientists for understanding the drug's efficacy and safety in people. Even in these phases, STEM skills continue to be crucial, from Statistics for analysing clinical data to Pharmacology for monitoring the drug's efficacy and safety.

Interdisciplinarity of STEM Skills

The drug discovery journey is a hymn to the synergy of STEM skills. A concrete example of how innovation does not arise from a single field but from the intersection of diverse disciplines. Interdisciplinarity is not just a complex word but the beating heart of the modern scientific method.

If Science (biology, chemistry) identifies the problem and addresses it at the molecular level, Technology (robotics, bioinformatics) provides the tools to scale the process and analyse data. Engineering (process chemistry, nanotechnologies) makes drug production and delivery possible, and Mathematics (statistics, modelling) ensures the robustness and scientific validity of every single discovery.

Every new drug that reaches the market is the result of thousands of data-driven decisions and an inexhaustible collaboration between different minds with different skills.

It is a striking demonstration that humanity's most complex challenges, such as the fight against disease, can only be overcome through a unified approach, where STEM skills merge into a single, powerful engine of development and progress.

And you — in which phase of this journey and with which STEM skills would you like to leave your mark?

FAQ

How long does it take to develop a new drug?

Complete development takes on average 12-15 years: 3-6 years for molecule discovery and optimisation, 2-3 years for preclinical studies, and 6-8 years for the three phases of human clinical trials. Only 1 molecule out of 10,000 tested reaches the market.

Which STEM skills are most in demand in the pharmaceutical industry?

Medicinal chemistry and molecular biology are central, but demand is rapidly growing for bioinformatics, data science, and machine learning for data analysis. Chemical engineering is fundamental for large-scale production, while statistics is essential for clinical trials.

What does "drug-like" mean in drug design?

A "drug-like" molecule meets certain physicochemical properties that make it suitable to become a drug: adequate solubility, ability to cross cell membranes, metabolic stability, and absence of known toxic groups. Lipinski's "Rule of 5" is one of the most commonly used criteria.

How does high-throughput screening (HTS) work?

HTS uses automated robots to test millions of chemical compounds in plates with hundreds of wells. Each well contains the biological target and a different compound. Optical sensors detect which compounds interact with the target, identifying potential "hits" in weeks rather than years.